Functional MRI for tumor delineation in prostate radiation therapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Imaging in Medicine

• Publication date

  2011-04-19

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.2217/IIM.11.10
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Diffusion weighted imaging in prostate cancer

  2011cited by this paper
• Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.

  2011cited by this paper
• MAGNETIC RESONANCE IMAGING IN PROSTATE CANCER : VALUE OF APPARENT DIFFUSION COEFFICIENTS FOR IDENTIFYING MALIGNANT NODULES

  2010cited by this paper
• Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation.

  2010cited by this paper
• Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection.

  2010cited by this paper
• Role of MRI in follow-up after focal therapy for prostate carcinoma.

  2010cited by this paper
• Dynamic contrast-enhanced CT for prostate cancer: relationship between image noise, voxel size, and repeatability.

  2010cited by this paper
• Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy.

  2010cited by this paper
• Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients.

  2010cited by this paper
• Supervised and unsupervised methods for prostate cancer segmentation with multispectral MRI.

  2010cited by this paper
• Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility‐weighted MRI parameters in the benign and malignant human prostate

  2010cited by this paper
• Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features.

  2010cited by this paper
• The use of probability maps to deal with the uncertainties in prostate cancer delineation.

  2010cited by this paper
• Intensity-Modulated Radiotherapy for Prostate Cancer Implementing Molecular Imaging with 18F-Choline PET-CT to Define a Simultaneous Integrated Boost

  2010cited by this paper
• The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer

  2010cited by this paper
• Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T.

  2009cited by this paper
• Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses.

  2009cited by this paper
• Validation of functional imaging with pathology for tumor delineation in the prostate.

  2009cited by this paper
• A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds.

  2009cited by this paper
• Dynamic MRI and CAD vs. Choline MRS: Where is the detection level for a lesion characterisation in prostate cancer?

  2009cited by this paper
• Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: A pilot study in men with prostate cancer

  2009cited by this paper
• Functional magnetic resonance imaging in prostate cancer.

  2009cited by this paper
• Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

  2009cited by this paper
• Benign prostatic hyperplasia: Evaluation of T1, T2, and microvascular characteristics with T1‐weighted dynamic contrast‐enhanced MRI

  2009cited by this paper
• Health‐related quality of life 3 years after high‐dose intensity‐modulated radiotherapy with gold fiducial marker‐based position verification

  2009cited by this paper
• Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose.

  2009cited by this paper
• Prostate cancer detection with multi‐parametric MRI: Logistic regression analysis of quantitative T2, diffusion‐weighted imaging, and dynamic contrast‐enhanced MRI

  2009cited by this paper
• Prostate cancer detection: comparison of t2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined

  2008cited by this paper
• The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery

  2008cited by this paper
• MR imaging of the prostate in clinical practice

  2008cited by this paper
• Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.

  2008cited by this paper
• Potential benefits of intra-prostatic cancer-specific imaging to guide therapy and monitor outcome in patients treated with radiation-based treatments for localized prostate cancer

  2008cited by this paper
• Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: Correlation with stepwise histopathology

  2008cited by this paper
• Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers.

  2008cited by this paper
• High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients

  2008cited by this paper
• Registration methodology for histological sections and in vivo imaging of human prostate.

  2008cited by this paper
• Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.

  2008cited by this paper
• Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI.

  2008cited by this paper
• Apparent diffusion coefficient values in peripheral and transition zones of the prostate: Comparison between normal and malignant prostatic tissues and correlation with histologic grade

  2008cited by this paper
• Combined T 2-weighted and diffusion-weighted MRI for localization of prostate cancer

  2007cited by this paper
• Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance.

  2007cited by this paper
• Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer.

  2007cited by this paper
• Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.

  2007cited by this paper
• Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility.

  2007cited by this paper
• Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection

  2007cited by this paper
• Repeatability of echo-planar-based diffusion measurements of the human prostate at 3 T.

  2007cited by this paper
• Imaging prostate cancer: a multidisciplinary perspective.

  2007cited by this paper
• Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines.

  2007cited by this paper
• Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations.

  2007cited by this paper
• Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging

  2007cited by this paper
• IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.

  2006cited by this paper
• How good is MRI at detecting and characterising cancer within the prostate?

  2006cited by this paper
• Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRI

  2006cited by this paper
• Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology

  2006cited by this paper
• Prostate cancer imaging.

  2006cited by this paper
• Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging.

  2006cited by this paper
• Prostate cancer: local staging at 3-T endorectal MR imaging--early experience.

  2006cited by this paper
• Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

  2006cited by this paper
• Feasibility and measurement precision of 3D quantitative blood flow mapping of the prostate using dynamic contrast-enhanced multi-slice CT

  2006cited by this paper
• Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions.

  2006cited by this paper
• Target definition in prostate, head, and neck.

  2005cited by this paper
• Dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) is a useful modality for the precise detection and staging of early prostate cancer

  2005cited by this paper
• Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.

  2005cited by this paper
• Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization.

  2005cited by this paper
• Wash‐in rate on the basis of dynamic contrast‐enhanced MRI: Usefulness for prostate cancer detection and localization

  2005cited by this paper
• Theragnostic imaging for radiation oncology: dose-painting by numbers.

  2005cited by this paper
• Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

  2005cited by this paper
• Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.

  2005cited by this paper
• Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience.

  2005cited by this paper
• The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy.

  2005cited by this paper
• Expandable and rigid endorectal coils for prostate MRI: Impact on prostate distortion and rigid image registration.

  2005cited by this paper
• Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists.

  2005cited by this paper
• Functional anatomy of the prostate: implications for treatment planning.

  2005cited by this paper
• Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging--initial experience.

  2004cited by this paper
• Combined quantitative dynamic contrast‐enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer

  2004cited by this paper
• Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings.

  2004cited by this paper
• Proton HR‐MAS spectroscopy and quantitative pathologic analysis of MRI/3D‐MRSI‐targeted postsurgical prostate tissues

  2003cited by this paper
• Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning.

  2002cited by this paper
• Reproducibility of quantitative dynamic MRI of normal human tissues

  2002cited by this paper
• Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.

  2002cited by this paper
• Functional CT imaging of prostate cancer.

  2001cited by this paper
• Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.

  2000cited by this paper
• Detailed mapping of prostate carcinoma foci

  2000cited by this paper
• Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols

  1999cited by this paper
• Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy.

  1999cited by this paper

• Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy

  2022cites this paper
• A study of the clinical, treatment planning and dosimetric feasibility of dose painting in external beam radiotherapy of prostate cancer

  2020cites this paper
• Modern Radiation Therapy Planning and Delivery.

  2019cites this paper
• The rationale for MR-only treatment planning for external radiotherapy

  2019cites this paper
• Impact of contrast agent injection duration on dynamic contrast‐enhanced MRI quantification in prostate cancer

  2018cites this paper
• A modeling study of functional magnetic resonance imaging to individualize target definition of seminal vesicles for external beam radiotherapy

  2017cites this paper
• Use of magnetic resonance imaging in radical prostate radiotherapy

  2016cites this paper
• The Potential for an Enhanced Role for MRI in Radiation-therapy Treatment Planning

  2013cites this paper
• Contemporary issues in radiotherapy for clinically localized prostate cancer.

  2013cites this paper
• Reducing the side effects of external beam radiotherapy in prostate cancer: role of imaging techniques

  2012cites this paper
• Dynamic contrast-enhanced (DCE) imaging for tumor delineation in prostate cancer

  2011cites this paper
• Functional MR Imaging for focal radiotherapy of prostate cancer

  2011cites this paper
• Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial

  2011cites this paper
• Role of MRI in follow-up after focal therapy for prostate carcinoma.

  2010cites this paper